Emerging at the UK, retatrutide, a novel molecule, is creating considerable interest within the scientific community regarding its promise for body management . This dual GIP and GLP-1 target agonist looks to provide a considerable advantage over established therapies, showing encouraging results in early clinical studies . Researchers suggest its